Drug Profile

HOPO 14-1

Alternative Names: HOPO 101; HOPO 141

Latest Information Update: 03 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator HOPO Therapeutics
Developer HOPO Therapeutics; SRI International
Class Antineoplastics; Radioprotectives; Small molecules
Mechanism of Action Chelating agents

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Radiation injuries

Most Recent Events

03 Oct 2025 Pharmacodynamics data from nonclinical studies in Radiation injuries released by HOPO Therapeutics
07 Dec 2022 US FDA approves IND application for HOPO 14-1 in Radiation injuries (HOPO Therapeutics pipeline, December 2022) (https://www.hopotx.com/about/)
06 Dec 2022 SRI International plans to initiate a phase I trial for Radiation injuries (PO) in December 2022 (NCT05628961)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com